English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 January 2011, 11:43 HKT/SGT
Share:
    

Source: China Medical System Holdings Limited
China Medical System Holdings Issues FY2010 Earnings Guidance

HONG KONG, Jan 12, 2011 - (ACN Newswire) - China Medical System Holdings Ltd. (HKSE:0867) expects to release its results for the year ended 31 December 2010 in early March 2011.

As the leading provider of marketing, promotion and sales services for prescription drugs in China, CMS maintained its rapid growth in 2010.

The unaudited sales for the year ended 31 December 2010 are expected to be approximately US$132.2 million which represents a year over year growth of approximately 37%; up from US$96.5 million for the year ended 31 December 2009.

The strong sales growth was largely a result of our continuous promotion and marketing activities of our existing products.

Contact:
Quam IR 
Ms Anita Wan
Tel: +852-2217-2687
E-mail: anita.wan@quamgroup.com

Ms Sharon Au
Tel: +852-2217-2680
E-mail: sharon.au@quamgroup.com
  
Ms Venus Lam
Tel: +852-2217-2909
E-mail: venus.lam@quamgroup.com






Topic: Press release summary
Source: China Medical System Holdings Limited

Sectors: Daily Finance, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

China Medical System Holdings Limited Related News
Apr 27, 2026 19:35 HKT/SGT
康哲藥業就已上市原研藥靜脈鐵劑莫諾菲和科莫非簽訂獨家商業化與供應協議
Apr 27, 2026 19:24 HKT/SGT
康哲药业就已上市原研药静脉铁剂莫诺菲和科莫非签订独家商业化与供应协议
Apr 27, 2026 19:00 HKT/SGT
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)
Apr 23, 2026 22:00 HKT/SGT
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
Apr 23, 2026 19:48 HKT/SGT
康哲药业:1类新药MG-K10季节性过敏性鼻炎适应症NDA获受理
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575